| PD-L1 on host cells is essential for PD-L1 blockade–mediated tumor regression H Tang, Y Liang, RA Anders, JM Taube, X Qiu, A Mulgaonkar, X Liu, ... The Journal of clinical investigation 128 (2), 580-588, 2018 | 482 | 2018 |
| PD-L1 on dendritic cells attenuates T cell activation and regulates response to immune checkpoint blockade Q Peng, X Qiu, Z Zhang, S Zhang, Y Zhang, Y Liang, J Guo, H Peng, ... Nature communications 11 (1), 4835, 2020 | 340 | 2020 |
| DNA sensing in mismatch repair-deficient tumor cells is essential for anti-tumor immunity C Lu, J Guan, S Lu, Q Jin, B Rousseau, T Lu, D Stephens, H Zhang, J Zhu, ... Cancer cell 39 (1), 96-108. e6, 2021 | 177 | 2021 |
| A next-generation tumor-targeting IL-2 preferentially promotes tumor-infiltrating CD8+ T-cell response and effective tumor control Z Sun, Z Ren, K Yang, Z Liu, S Cao, S Deng, L Xu, Y Liang, J Guo, Y Bian, ... Nature communications 10 (1), 3874, 2019 | 164 | 2019 |
| Innate lymphoid cells control early colonization resistance against intestinal pathogens through ID2-dependent regulation of the microbiota X Guo, Y Liang, Y Zhang, A Lasorella, BL Kee, YX Fu Immunity 42 (4), 731-743, 2015 | 122 | 2015 |
| Androgen receptor antagonists compromise T cell response against prostate cancer leading to early tumor relapse Y Pu, M Xu, Y Liang, K Yang, Y Guo, X Yang, YX Fu Science translational medicine 8 (333), 333ra47-333ra47, 2016 | 109 | 2016 |
| A dendritic-cell-stromal axis maintains immune responses in lymph nodes V Kumar, DC Dasoveanu, S Chyou, TC Tzeng, C Rozo, Y Liang, W Stohl, ... Immunity 42 (4), 719-730, 2015 | 82 | 2015 |
| Targeting IFNα to tumor by anti-PD-L1 creates feedforward antitumor responses to overcome checkpoint blockade resistance Y Liang, H Tang, J Guo, X Qiu, Z Yang, Z Ren, Z Sun, Y Bian, L Xu, H Xu, ... Nature communications 9 (1), 4586, 2018 | 79 | 2018 |
| Selective delivery of low-affinity IL-2 to PD-1+ T cells rejuvenates antitumor immunity with reduced toxicity Z Ren, A Zhang, Z Sun, Y Liang, J Ye, J Qiao, B Li, YX Fu The Journal of clinical investigation 132 (3), 2022 | 48 | 2022 |
| CTLA-4 limits anti-CD20–mediated tumor regression Z Ren, J Guo, J Liao, Y Luan, Z Liu, Z Sun, X Liu, Y Liang, H Peng, YX Fu Clinical Cancer Research 23 (1), 193-203, 2017 | 48 | 2017 |
| Next generation of tumor-activating type I IFN enhances anti-tumor immune responses to overcome therapy resistance X Cao, Y Liang, Z Hu, H Li, J Yang, EJ Hsu, J Zhu, J Zhou, YX Fu Nature communications 12 (1), 5866, 2021 | 47 | 2021 |
| Tumor-conditional IL-15 pro-cytokine reactivates anti-tumor immunity with limited toxicity J Guo, Y Liang, D Xue, J Shen, Y Cai, J Zhu, YX Fu, H Peng Cell Research 31 (11), 1190-1198, 2021 | 42 | 2021 |
| Targeting tumors with IL-21 reshapes the tumor microenvironment by proliferating PD-1intTim-3–CD8+ T cells S Deng, Z Sun, J Qiao, Y Liang, L Liu, C Dong, A Shen, Y Wang, H Tang, ... JCI insight 5 (7), 2020 | 38 | 2020 |
| Type I IFN activating type I dendritic cells for antitumor immunity Y Liang, R Hannan, YX Fu Clinical Cancer Research 27 (14), 3818-3824, 2021 | 28 | 2021 |
| STING-cytosolic DNA sensing: the backbone for an effective tumor radiation therapy Y Liang, H Peng Annals of translational medicine 4 (3), 2016 | 21 | 2016 |
| Engineered anti-PDL1 with IFNα targets both immunoinhibitory and activating signals in the liver to break HBV immune tolerance CY Meng, S Sun, Y Liang, H Xu, C Zhang, M Zhang, FS Wang, YX Fu, ... Gut 72 (8), 1544-1554, 2023 | 13 | 2023 |
| An engineered concealed IL-15-R elicits tumor-specific CD8+T cell responses through PD-1-cis delivery J Shen, Z Zou, J Guo, Y Cai, D Xue, Y Liang, W Wang, H Peng, YX Fu Journal of Experimental Medicine 219 (12), e20220745, 2022 | 11 | 2022 |
| Deficiency of CD40 reveals an important role for LIGHT in anti-leishmania immunity I Okwor, G Xu, H Tang, Y Liang, YX Fu, JE Uzonna The Journal of Immunology 195 (1), 194-202, 2015 | 11 | 2015 |
| Innate lymphotoxin receptor mediated signaling promotes HSV-1 associated neuroinflammation and viral replication Y Liang, K Yang, J Guo, J Wroblewska, YX Fu, H Peng Scientific reports 5 (1), 10406, 2015 | 10 | 2015 |
| T cell-derived lymphotoxin is essential for the anti-herpes simplex virus 1 humoral immune response K Yang, Y Liang, Z Sun, D Xue, H Xu, M Zhu, YX Fu, H Peng Journal of virology 92 (14), 10.1128/jvi. 00428-18, 2018 | 7 | 2018 |
Yang-Xin FuTsinghua UniversityVerified email at tsinghua.edu.cn
